(talazoparib)

Medication Guide

Download Consumer Medicine Information

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Prescribing Information

Download Prescribing Information

Health Professional Information

What is TALZENNA?

What is TALZENNA?

alone to treat adults with human epidermal growth factor receptor 2 (HER2)-negative breast cancer:
o
who have a certain type of an abnormal inherited BRCA gene, and
o
whose cancer has spread to other parts of the body (locally advanced or metastatic).
 
Your healthcare provider will perform a test to make sure that TALZENNA is right for you.
in combination with a medicine called enzalutamide, to treat adults with prostate cancer
o
with certain abnormal inherited or acquired genes called homologous recombination repair (HRR genes) and
o
which no longer responds to hormone therapy or surgical treatment to lower testosterone and has spread to other parts of the body (metastatic).
 
Your healthcare provider will perform a test to make sure that TALZENNA is right for you.

It is not known if TALZENNA is safe and effective in children.

Before taking TALZENNA, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problems.
are pregnant or plan to become pregnant. TALZENNA can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with TALZENNA.
 
Females who are able to become pregnant:
o
Your healthcare provider may do a pregnancy test before you start treatment with TALZENNA.
o
You should use effective birth control (contraception) during treatment with TALZENNA and for 7 months after the last dose of TALZENNA. Talk to your healthcare provider about forms of birth control that may be right for you.
o
Tell your healthcare provider right away if you are pregnant or think you are pregnant during treatment with TALZENNA.
 
Males with female partners who are pregnant or are able to become pregnant:
o
You should use effective birth control during treatment with TALZENNA and for 4 months after the last dose of TALZENNA.
are breastfeeding or plan to breastfeed. It is not known if TALZENNA passes into your breast milk. Do not breastfeed during treatment with TALZENNA and for 1 month after the last dose of TALZENNA. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TALZENNA with certain other medicines can affect how TALZENNA works and may cause side effects.
Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.